Full text biomedical articles

Spironolactone is an antagonist of NRG1‐ERBB4 signaling and schizophrenia‐relevant endophenotypes in mice

Michael C Wehr, Wilko Hinrichs, Magdalena M Brzózka, Tilmann Unterbarnscheidt, Alexander Herholt, Jan P Wintgens, Sergi Papiol, Maria Clara Soto‐Bernardini, Mykola Kravchenko, Mingyue Zhang, Klaus‐Armin Nave, Sven P Wichert, Peter Falkai, Weiqi Zhang, Markus H Schwab, Moritz J Rossner
EMBO Mol Med. 2017 Oct; 9(10): 1448–1462. Published online 2017 Jul 25. doi: 10.15252/emmm.201707691


Article   |   PubReader   |   PDF–927K   |   Cite

Spotlight on Spironolactone Oral Suspension for the Treatment of Heart Failure: Focus on Patient Selection and Perspectives

Antonis A Manolis, Theodora A Manolis, Helen Melita, Antonis S Manolis
Vasc Health Risk Manag. 2019; 15: 571–579. Published online 2019 Dec 30. doi: 10.2147/VHRM.S210150


Article   |   PubReader   |   PDF–323K   |   Cite

Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review

Alison M. Layton, E. Anne Eady, Heather Whitehouse, James Q. Del Rosso, Zbys Fedorowicz, Esther J. van Zuuren
Am J Clin Dermatol. 2017; 18(2): 169–191. Published online 2017 Feb 2. doi: 10.1007/s40257-016-0245-x


Article   |   PubReader   |   PDF–820K   |   Cite

The mineralocorticoid receptor antagonist spironolactone reduces alcohol self- administration in female and male rats

Viren H. Makhijani, Kalynn Van Voorhies, Joyce Besheer
Pharmacol Biochem Behav. Author manuscript; available in PMC 2019 Dec 1.
Published in final edited form as: Pharmacol Biochem Behav. 2018 Dec; 175: 10–18. Published online 2018 Aug 29. doi: 10.1016/j.pbb.2018.07.011


Article   |   PubReader   |   PDF–643K   |   Cite

Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data

Megan Shuey, Bradley Perkins, Hui Nian, Chang Yu, James M Luther, Nancy Brown
BMJ Open. 2020; 10(5): e033100. Published online 2020 May 26. doi: 10.1136/bmjopen-2019-033100


Article   |   PubReader   |   PDF–1.1M   |   Cite

Pannexin 1 Channels as an Unexpected New Target of the Anti-Hypertensive Drug Spironolactone

Miranda E. Good, Yu-Hsin Chiu, Ivan K. H. Poon, Chris Medina, Joshua T. Butcher, Suresh K. Mendu, Leon J. DeLalio, Alexander W. Lohman, Norbert Leitinger, Eugene Barrett, Ulrike M. Lorenz, Bimal N. Desai, Iris Z. Jaffe, Douglas A. Bayliss, Brant E. Isakson, Kodi S. Ravichandran
Circ Res. Author manuscript; available in PMC 2019 Feb 16.
Published in final edited form as: Circ Res. 2018 Feb 16; 122(4): 606–615. Published online 2017 Dec 13. doi: 10.1161/CIRCRESAHA.117.312380


Article   |   PubReader   |   PDF–2.1M   |   Cite

Spironolactone metabolite concentrations in decompensated heart failure: Insights from the ATHENA-HF trial.

Simon de Denus, Grégoire Leclair, Marie-Pierre Dubé, Isabelle St-Jean, Yassamin Feroz Zada, Essaïd Oussaïd, Martin Jutras, Michael M. Givertz, Robert J. Mentz, W. H. Wilson Tang, João P Ferreira, Jean Rouleau, Javed Butler, Andreas P. Kalogeropoulos
Eur J Heart Fail. Author manuscript; available in PMC 2021 Aug 1.
Published in final edited form as: Eur J Heart Fail. 2020 Aug; 22(8): 1451–1461. Published online 2020 Apr 1. doi: 10.1002/ejhf.1802


Article   |   PubReader   |   PDF–756K   |   Cite

Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE/RAGE axis in a chronic renal failure rat model

Chun-Cheng Wang, An-Sheng Lee, Shu-Hui Liu, Kuan-Cheng Chang, Ming-Yi Shen, Chiz-Tzung Chang
BMC Nephrol. 2019; 20: 351. Published online 2019 Sep 6. doi: 10.1186/s12882-019-1534-4


Article   |   PubReader   |   PDF–2.1M   |   Cite

Interventions for hirsutism (excluding laser and photoepilation therapy alone)

Esther J van Zuuren, Zbys Fedorowicz, Ben Carter, Nikolaos Pandis
Cochrane Database Syst Rev. 2015 Apr; 2015(4): CD010334. Published online 2015 Apr 28. doi: 10.1002/14651858.CD010334.pub2


Article   |   PubReader   |   PDF–6.6M   |   Cite

Spironolactone use and risk of incident cancers: a retrospective, matched cohort study

Isla S. Mackenzie, Steven V. Morant, Li Wei, Alastair M. Thompson, Thomas M. MacDonald
Br J Clin Pharmacol. 2017 Mar; 83(3): 653–663. Published online 2016 Nov 12. doi: 10.1111/bcp.13152


Article   |   PubReader   |   PDF–742K   |   Cite

Clinical efficacy and safety of spironolactone in patients with resistant hypertension: A systematic review and meta-analysis

Cong Chen, Xue-Ying Zhu, Dong Li, Qian Lin, Kun Zhou
Medicine (Baltimore) 2020 Aug 21; 99(34): e21694. Published online 2020 Aug 21. doi: 10.1097/MD.0000000000021694


Article   |   PubReader   |   PDF–2.5M   |   Cite

National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011

Wenchi Guan, Karthik Murugiah, Nicholas Downing, Jing Li, Qing Wang, Joseph S Ross, Nihar R Desai, Frederick A Masoudi, John A Spertus, Xi Li, Harlan M Krumholz, Lixin Jiang, for the China PEACE Collaborative Group
J Am Heart Assoc. 2015 Jun; 4(6): e001718. Published online 2015 Jun 12. doi: 10.1161/JAHA.114.001718


Article   |   PubReader   |   PDF–485K   |   Cite

Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes

Dan Dong, Ting-ting Fan, Ying-shi Ji, Jin-yu Yu, Shan Wu, Li Zhang
Int Urol Nephrol. 2019; 51(4): 755–764. Published online 2019 Feb 8. doi: 10.1007/s11255-019-02074-9


Article   |   PubReader   |   PDF–5.9M   |   Cite

In Vitro and In Vivo Studies of Spironolactone as an Antischistosomal Drug Capable of Clinical Repurposing

Rafael A. Guerra, Marcos P. Silva, Tais C. Silva, Maria C. Salvadori, Fernanda S. Teixeira, Rosimeire N. de Oliveira, Jefferson A. Rocha, Pedro L. S. Pinto, Josué de Moraes
Antimicrob Agents Chemother. 2019 Mar; 63(3): e01722-18. Prepublished online 2018 Dec 17. Published online 2019 Feb 26. doi: 10.1128/AAC.01722-18


Article   |   PubReader   |   PDF–1.2M   |   Cite

Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat

Catherine J. Leader, Darren J. Kelly, Ivan A. Sammut, Gerard T. Wilkins, Robert J. Walker
Physiol Rep. 2020 May; 8(10): e14448. Published online 2020 May 22. doi: 10.14814/phy2.14448


Article   |   PubReader   |   PDF–1.6M   |   Cite

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia

Mark Bounthavong, Javed Butler, Chantal M. Dolan, Jeffrey D. Dunn, Kathryn A. Fisher, Nina Oestreicher, Bertram Pitt, Paul J. Hauptman, David L. Veenstra
Pharmacoeconomics. 2018; 36(12): 1463–1473. Published online 2018 Sep 8. doi: 10.1007/s40273-018-0709-3


Article   |   PubReader   |   PDF–890K   |   Cite

Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction

Essraa Bayoumi, Phillip H. Lam, Daniel J. Dooley, Steven Singh, Charles Faselis, Charity J. Morgan, Samir Patel, Helen M. Sheriff, Selma F. Mohammed, Carlos E. Palant, Bertram Pitt, Gregg C. Fonarow, Ali Ahmed
Am J Med. Author manuscript; available in PMC 2020 Jan 1.
Published in final edited form as: Am J Med. 2019 Jan; 132(1): 71–80.e1. Published online 2018 Sep 19. doi: 10.1016/j.amjmed.2018.09.011


Article   |   PubReader   |   PDF–1.2M   |   Cite

Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration

Min Zhao, Irmela Mantel, Emmanuelle Gelize, Xinxin Li, Xiaoyue Xie, Alejandro Arboleda, Marie Seminel, Rinath Levy-Boukris, Marilyn Dernigoghossian, Andrea Prunotto, Charlotte Andrieu-Soler, Carlo Rivolta, Jérémie Canonica, Marie-Christine Naud, Sebastian Lechner, Nicolette Farman, Irene Bravo-Osuna, Rocio Herrero-Vanrell, Frederic Jaisser, Francine Behar-Cohen
Nat Commun. 2019; 10: 369. Published online 2019 Jan 21. doi: 10.1038/s41467-018-08125-6


Article   |   PubReader   |   PDF–1.6M   |   Cite

Molecular evolution of the switch for progesterone and spironolactone from mineralocorticoid receptor agonist to antagonist

Peter J. Fuller, Yi-Zhou Yao, Ruitao Jin, Sitong He, Beatriz Martín-Fernández, Morag J. Young, Brian J. Smith
Proc Natl Acad Sci U S A. 2019 Sep 10; 116(37): 18578–18583. Published online 2019 Aug 22. doi: 10.1073/pnas.1903172116


Article   |   PubReader   |   PDF–978K   |   Cite

Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs

Wennan Li, Xingjuan Chen, Ashley M. Riley, S. Christopher Hiett, Constance J. Temm, Eleni Beli, Xin Long, Saikat Chakraborty, Mouhamad Alloosh, Fletcher A. White, Maria B. Grant, Michael Sturek, Alexander G. Obukhov
Basic Res Cardiol. 2017; 112(5): 54. Published online 2017 Jul 29. doi: 10.1007/s00395-017-0643-0


Article   |   PubReader   |   PDF–17M   |   Cite